• FutureChem disclosed topline results received Oct. 23, 2026, from a US Phase 2a trial of lutetium-177 ludotadipep for metastatic castration-resistant prostate cancer.
• The treatment produced complete or partial tumor responses in some patients, with disease control in most evaluable participants.
• A clinical study report is expected by year-end; safety and survival follow-up remains ongoing, with completion expected in February 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FutureChem Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261023900540), on October 23, 2026, and is solely responsible for the information contained therein.